Oxurion NV

LSE (EUR): Oxurion NV (0G99)

Last Price

0.00

Today's Change

0.00 (0.00%)

Day's Change

0.00 - 0.00

Trading Volume

2,000

Overview

Market Cap

901,482

Shares Outstanding

9 Billion

Avg Volume

8,955

Avg Price (50 Days)

0.00

Avg Price (200 Days)

0.00

PE Ratio

0.00

EPS

-0.76

Earnings Announcement

30-Sep-2024

Previous Close

0.00

Open

0.00

Day's Range

1.0E-4 - 1.0E-4

Year Range

1.0E-4 - 0.0122

Trading Volume

1,000

Price Change Highlight

1 Day Change

0.00%

5 Day Change

0.00%

1 Month Change

0.00%

3 Month Change

-75.00%

6 Month Change

-85.71%

Ytd Change

-75.00%

1 Year Change

-98.68%

3 Year Change

-100.00%

5 Year Change

-100.00%

10 Year Change

-100.00%

Max Change

-100.00%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Pharmaceuticals, Biotechnology & Life Sciences

Description:

Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment